S
Sören Lehmann
Researcher at Karolinska University Hospital
Publications - 20
Citations - 3737
Sören Lehmann is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 5, co-authored 6 publications receiving 2950 citations.
Papers
More filters
Journal ArticleDOI
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese,Anna K. Kähler,Robert E. Handsaker,Johan Lindberg,Samuel A. Rose,Samuel F. Bakhoum,Kimberly Chambert,Eran Mick,Benjamin M. Neale,Menachem Fromer,Shaun Purcell,Oscar Svantesson,Mikael Landén,Martin Höglund,Sören Lehmann,Stacey Gabriel,Jennifer L. Moran,Eric S. Lander,Patrick F. Sullivan,Pamela Sklar,Henrik Grönberg,Christina M. Hultman,Steven A. McCarroll +22 more
TL;DR: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death.
Journal ArticleDOI
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson,Petar Antunovic,Åsa Rangert Derolf,Sören Lehmann,Lars Möllgård,Dick Stockelberg,Ulf Tidefelt,Anders Wahlin,Martin Höglund +8 more
TL;DR: Standard intensive treatment improves early death rates and long-term survival compared with palliation and most AML patients up to 80 years of age should be considered fit for intensive therapy, and new therapies must be compared with standard induction.
Journal ArticleDOI
Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry
Erik Hulegårdh,Christer Nilsson,Vladimir Lazarevic,Hege Garelius,Petar Antunovic,Åsa Rangert Derolf,Lars Möllgård,Bertil Uggla,Lovisa Wennström,Anders Wahlin,Martin Höglund,Gunnar Juliusson,Dick Stockelberg,Sören Lehmann +13 more
TL;DR: It is concluded that secondary AML in a population‐based setting has a striking impact on survival in younger AML patients, whereas it lacks prognostic value among the elderly patients.
Journal ArticleDOI
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
Martin Höglund,Fredrik Sandin,Karin Hellström,Mats Björeman,Magnus Björkholm,Mats Brune,Arta Dreimane,Marja Ekblom,Sören Lehmann,Per Ljungman,Claes Malm,Berit Markevärn,Kristina Myhr-Eriksson,Lotta Ohm,Ulla Olsson-Strömberg,Anders Själander,Hans Wadenvik,Bengt Simonsson,Leif Stenke,Johan Richter +19 more
TL;DR: Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival, and high-risk scores were significantly linked to inferior overall and relative survival.
Journal ArticleDOI
Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation
Michelle Rönnerblad,Robin Andersson,Tor Olofsson,Iyadh Douagi,Mohsen Karimi,Sören Lehmann,Ilka Hoof,Michiel J. L. de Hoon,Masayoshi Itoh,Sayaka Nagao-Sato,Hideya Kawaji,Timo Lassmann,Piero Carninci,Yoshihide Hayashizaki,Alistair R. R. Forrest,Albin Sandelin,Karl Ekwall,Erik Arner,Andreas Lennartsson +18 more
TL;DR: Overall, this study depicts in detail the epigenetic and transcriptional changes that occur during granulopoiesis and supports the role of DNA methylation as a regulatory mechanism in blood cell differentiation.